Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (301)	8/14/1999 7:31:00 AM
From: Harold Lehman	Read Replies (1) \| Respond to of 1137

I don't know anything about the convertible issues, but I'll attempt to answer some of your other questions. The Phase 2/3 trial of CPX, the cystic fibrosis drug, should be done with by the end of the year (originally it was supposed to be the end of summer). Since it has orphan drug status it could get pretty quick approval if the trial results are good enough. My own view of their science regarding Zadaxin (thymosin) in the hepatitis B & C trials is that it definitely looks like it's decreasing viral load. However, I do not know why they didn't measure levels of hepatitis B surface antigen more frequently. If I recall in the one study that I think they measured it, it did not decrease while other viral parameters diminished, including viral load. Maybe early in the infection a load of B surface antigen is synthesized, stored, and released slowly over time (all this is my own hypothesis and probably wrong) so that there was not enough time in that trial for it to diminish. In the studies where they did liver biopsies they showed less liver scarring and histological damage after treatment. I thought they should have done more of these studies. Their web site is: sciclone.com Sorry this response took so long. Regards, Harold